EYPT250117C25000
- 0.10
- 0.000.00%
EyePoint Pharmaceuticals Newsroom
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
EyePoint Pharmaceuticals Analyst Ratings
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $22
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Price Target Cut to $22.00/Share From $30.00 by HC Wainwright & Co.
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $33
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $20
EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
EyePoint Pharmaceuticals Analyst Ratings
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
JonesTrading Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $45
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $38
Analyst Ratings For EyePoint Pharmaceuticals